Eterna Therapeutics Inc.
ERNA
$-0.10
Change (1 day)
$2.63
Year High
$0.52
Year Low
Categories
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
P/S ratio for Eterna Therapeutics Inc. (ERNA)
P/S ratio as of 2023: 140.66
According to Eterna Therapeutics Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 140.66. At the end of 2022 the company had a P/S ratio of 0.00.
P/S ratio history for Eterna Therapeutics Inc. from 2015 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 140.66 |
| 2022 | 0.00 |
| 2021 | 0.00 |
| 2020 | 0.00 |
| 2019 | 0.32 |
| 2018 | 0.22 |
| 2017 | 0.48 |
| 2016 | 0.72 |
| 2015 | 0.60 |